Option chain shows key data for Quoin Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Quoin Pharmaceuticals.

Quoin Pharmaceuticals (NASDAQ:QNRX) Stock, Option Chain

Quoin Pharmaceuticals

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATNF

BREA

CLMT

CTCX

EFSH

GEVO

GRTS

KLTO

LCID

MTEM

PRQR

QNRX

SAIH

STAF

STEC

VINE

VSME

Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

oracle shutter

AMZN

ASNS

CNET

CNTM

EGIO

IONS

NUVB

ORCL

PSIG

RBRK

SGLY

SLXN

SMTK

TVGN

VRDN

WENA

WHLR

Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Earnings

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

AISP

APGE

CNSL

DAVE

TDUP

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday.

The Dow traded down 0.91% to 38,633.24 while the NASDAQ fell 1.85% to 15,906.92. The S&amp;P 500 also fell, dropping, 1.05% to 5,076.98.

Crude Oil Down 1%; Dave Shares Jump After Q4 Results

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals Ltd

Ex-President Bill Clinton has been hospitalized in Washington due to a fever on Monday, according to a report.
Clinton was admitted to MedStar Georgetown University Hospital in the afternoon for tests and observation after he developed a fever. Deputy Chief of Staff for the former President, Angel Ureña, shared this news on X. The post was first <a href="https://thehill.com/policy/healthcare/5054369-bill-clinton-hospitalized-fever/">noted</a> on The Hill.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">President Clinton was admitted to MedStar Georgetown University Hospital this afternoon for testing and observation after developing a fever. He remains in good spirits and deeply appreciates the excellent care he is receiving.
&mdash; Angel Ureña (@angelurena) <a href="https://twitter.com/angelurena/status/1871326214096372135?ref_src=twsrc%5Etfw">December 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ureña said, &#8220;He remains in good spirits and deeply appreciates the excellent care he is receiving.&#8221;
It is worth mentioning that Clinton was previously hospitalized for five days in 2021 due to sepsis caused by an infection, according to The Hill.
See Also: <a href="https://www.benzinga.com/24/12/42637260/elon-musk-accused-of-bullying-republicans-to-scrap-us-china-investment-safeguards-to-protect-teslas-interests?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Accused Of Bullying Republicans To Scrap US-China Investment Safeguards To Protect Tesla&#8217;s Interests</a>
Clinton had been <a href="https://www.benzinga.com/general/politics/24/08/40513316/bill-clinton-contrasts-harris-trump-in-fiery-dnc-speech-we-have-a-clear-choice-we-the-people-ver">actively campaigning</a> for Vice President Kamala Harris throughout the fall. Clinton had made a strong case for Harris during his speech at the Democratic National Convention (DNC).
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Bill Clinton Admitted To Hospital Due To Fever In Washington

Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) has outperformed the market over the past 10 years by 1.29% on an annualized basis producing an average annual return of 12.39%. Currently, Linde has a market capitalization of $201.03 billion. 
Buying $1000 In LIN: If an investor had bought $1000 of LIN stock 10 years ago, it would be worth $3,191.73 today based on a price of $421.00 for LIN at the time of writing.
<h3>Linde's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734997509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Linde 10 Years Ago Would Be Worth Today

Agnico Eagle Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) has outperformed the market over the past 10 years by 1.05% on an annualized basis producing an average annual return of 12.15%. Currently, Agnico Eagle Mines has a market capitalization of $39.61 billion. 
Buying $100 In AEM: If an investor had bought $100 of AEM stock 10 years ago, it would be worth $330.84 today based on a price of $78.99 for AEM at the time of writing.
<h3>Agnico Eagle Mines's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734996621_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Agnico Eagle Mines 10 Years Ago Would Be Worth This Much Today

Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has outperformed the market over the past 5 years by 6.87% on an annualized basis producing an average annual return of 19.87%. Currently, Goldman Sachs Gr has a market capitalization of $180.39 billion. 
Buying $100 In GS: If an investor had bought $100 of GS stock 5 years ago, it would be worth $246.87 today based on a price of $571.21 for GS at the time of writing.
<h3>Goldman Sachs Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734994828_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Goldman Sachs Gr 5 Years Ago Would Be Worth Today

WIIM

NEUE

NeueHealth shares are trading higher after the company announced it has entered into an definitive merger to be acquired for $7.33 per share.

NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>), the value-driven healthcare company, today announced that it has entered into a definitive merger agreement pursuant to which the Company will be acquired by an affiliate of New Enterprise Associates ("NEA") at an enterprise value of approximately $1.3 billion. Upon completion of the transaction, NeueHealth will become a privately held company with the flexibility and resources to continue advancing its value-driven, consumer-centric care model.
Under the terms of the merger agreement, holders of NeueHealth common stock (other than shares that will be rolled over and certain excluded shares) will receive $7.33 per share in cash, which represents a premium of approximately 70% over the closing price of NeueHealth common stock on December 23, 2024. Certain stockholders of NeueHeath, including NEA and 12 existing NeueHealth investors (which collectively hold all of the outstanding shares of NeueHealth preferred stock), have entered into rollover agreements pursuant to which such stockholders will continue their investments by exchanging their shares of NeueHealth common stock and/or preferred stock for newly issued equity interests in the privately held company, and the Company's existing secured loan facility with Hercules Capital, Inc. will remain in place.
NeueHealth's executive leadership team will continue in their roles upon completion of the transaction and intends to roll over 100% of their equity interests for newly issued equity interests in the privately held company.

NeueHealth  Entered Into A Definitive Merger Agreement To Be Acquired By An Affiliate Of New Enterprise Associates At An Enterprise Value Of ~$1.3B, Or $7.33/Share In Cash

INSW

International Seaways shares are trading higher after it was announced that the company will join the S&P SmallCap 600 on December 30, 2024.

International Seaways Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSW#NYSE">INSW</a>) will replace Consolidated Communications Holdings (NASD: CNSL) in the S&amp;P SmallCap 600 effective prior to the opening of trading on Monday, December 30. Searchlight Capital Partners and British Columbia Investment Management Corporation (BCI) are acquiring Consolidated Communications in a deal expected to be completed soon, pending final closing conditions.

International Seaways To Join S&P SmallCap 600 On Monday, December 30, 2024

CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) has outperformed the market over the past 5 years by 3.45% on an annualized basis producing an average annual return of 16.45%. Currently, CBRE Group has a market capitalization of $39.94 billion. 
Buying $100 In CBRE: If an investor had bought $100 of CBRE stock 5 years ago, it would be worth $212.97 today based on a price of $130.51 for CBRE at the time of writing.
<h3>CBRE Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734993914_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBRE

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

CREV

Carbon Revolution shares are trading higher after the company announced it has reached an agreement with OIC for a further $25 million in financing to support the ongoing liquidity of the business.

Carbon Revolution plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) (the "Company"), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology automotive carbon fiber wheels, today announced that it has reached an agreement with Orion Infrastructure Capital ("OIC") for a further US$25 million financing, which will be released in five tranches, each equal to US$5 million, subject to satisfying certain release conditions. In connection with the release of each of the five tranches of US$5 million, the Company will issue to OIC and the lenders under the US$60 million PIUS loan entered into in May 2023 ("Existing Noteholders"), penny warrants to purchase an aggregate number of shares equal to 5.0% of the Company's shares outstanding.

Financing

Carbon Revolution Has Reached An Agreement With Orion Infrastructure Capital For A Further $25M Financing, Which Will Be Released In 5 Tranches, Each Equal To $5M

CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) has outperformed the market over the past 5 years by 36.5% on an annualized basis producing an average annual return of 49.5%. Currently, CrowdStrike Holdings has a market capitalization of $88.93 billion. 
Buying $1000 In CRWD: If an investor had bought $1000 of CRWD stock 5 years ago, it would be worth $7,301.27 today based on a price of $361.06 for CRWD at the time of writing.
<h3>CrowdStrike Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734993015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRWD

$1000 Invested In CrowdStrike Holdings 5 Years Ago Would Be Worth This Much Today

Streaming giant Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is set to release the highly anticipated second season of "Squid Game" on Dec. 26, adding to an exciting month with its first live NFL games <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41123711/netflix-stock-could-get-boost-from-nfl-games-squid-game-season-2-analyst-says-conte">on Christmas Day.</a>
A Benzinga reader poll shows the second season might face more of an uphill battle for viewers compared to the first season in 2021.
What Happened: Released in September 2021, "Squid Game" <a href="https://www.benzinga.com/general/entertainment/24/12/42305013/squid-game-season-2-includes-new-games-contestant-with-a-crypto-background-revenge-factor-political-overtones">shattered viewership records </a>for Netflix with 1.65 billion hours watched in the first four weeks of availability.
The series became a massive hit and pop culture phenomenon and fans have eagerly been awaiting a second season.
Netflix will premiere all seven episodes of the second season on Dec. 26, beginning at 3 a.m. ET. Benzinga recently polled readers to see how eager people are to watch the new season.
"Will you be watching ‘Squid Game' season 2?" Benzinga asked.
The results were:
<ul>
<li>No, I don't plan to watch: 70%</li>
<li>Yes, I'll binge-watch the entire season when it's out: 21%</li>
<li>Yes, I'll watch each episode as soon as I can: 9%</li>
</ul>
The poll found that Benzinga readers are less excited about the second season compared to the interest generated by the first season.
The day-after-Christmas release could be a double-edged sword for Netflix. While the timing benefits from people being off work, it also coincides with family gatherings that might limit viewership.
Netflix will <a href="https://www.benzinga.com/general/entertainment/24/12/42657482/mrbeast-dominates-prime-video-how-youtuber-could-help-amazon-boost-streaming-presence">also be competing</a> with MrBeast's "Beast Games," a record-breaking game show on Amazon.com's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Prime Video. &#8220;Beast Games&#8221; released its first two episodes on Dec. 19 with a third episode coming on Dec. 26. The show features elements similar to the contests featured in &#8220;Squid Game.&#8221;
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/12/42563662/streamers-max-paramount-won-november-heres-why-analyst-expects-netflix-amazon-to-win-december">Streamers Max, Paramount+ Won November: Here&#8217;s Why Analyst Expects Netflix, Amazon To Win December</a>
What's Next: The second season of "Squid Game" will bring back several cast members from the first season. The new season has already been <a href="https://www.benzinga.com/general/entertainment/24/12/42395178/golden-globes-2025-nominations-netflix-scores-nods-for-emilia-perez-and-squid-game-comcast-lands-4-wicked-noms">nominated for a Golden Globe</a> and could become a favorite on the awards circuit, given more hype around the show this time.
Returning for the second season is the winner of the game in the first season, Seong Gi-hun (aka Player 456), portrayed on screen by&nbsp;Lee Jung-jae.&nbsp;Director and writer&nbsp;Hwang Dong-Hyuk&nbsp;also returns for the second season.
The second season features new characters and revolves around Gi-hun, who returns to the game three years after the competition to search for the people behind it and shut it down for good, as reported by <a href="https://deadline.com/2024/12/squid-game-season-2-explained-hwang-dong-hyuk-lee-jung-jae-1236189235/" target="_blank" rel="noreferrer noopener">Deadline</a>.
This time, characters competing for the prize include a former cryptocurrency influencer who loses a large amount of money for his subscribers and himself. The crypto influencer becomes a fugitive before joining the Squid Game competition, according to the report.
Another one of the 400-plus contestants in the games is a woman who made bad investments following the advice of the same cryptocurrency influencer taking part in the games.
Following the second season, a third and final season of the hit show will be released in 2025. Director Hwang said the second and third seasons were written at the same time and both were produced simultaneously. The third season is currently in the post-production process, the director said.
The first season of "Squid Game" has been watched by a total of 330 million viewers and a total of 2.8 billion hours have been streamed since the release, as reported by <a href="https://variety.com/2024/tv/news/squid-game-viewers-netflix-seoul-experience-1236232449/">Variety</a>. The overall metrics and the first four weeks&#8217; totals for the second season will be used to compare the success of the newest season.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42653325/exclusive-netflix-to-have-merry-christmas-with-nfl-games-will-viewers-tune-in-60-say">EXCLUSIVE: Netflix To Have Merry Christmas With NFL Games, Will Viewers Tune In? 60% Say…</a></li>
</ul>
The study was conducted by Benzinga from Dec. 18 through Dec. 19, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 145 adults.
Photo by DANIEL CONSTANTE on Shutterstock

Entertainment

Exclusives

NFLX

EXCLUSIVE: 'Squid Game' Broke Netflix Records, Will Viewers Watch Season 2? 70% Of Benzinga Readers Say…

American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) has outperformed the market over the past 20 years by 3.99% on an annualized basis producing an average annual return of 12.27%. Currently, American Tower has a market capitalization of $87.84 billion. 
Buying $1000 In AMT: If an investor had bought $1000 of AMT stock 20 years ago, it would be worth $10,289.06 today based on a price of $187.97 for AMT at the time of writing.
<h3>American Tower's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734992108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In American Tower 20 Years Ago Would Be Worth This Much Today

Four Corners Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCPT#NYSE">FCPT</a>), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties ("FCPT" or the "Company"), is pleased to announce the acquisition of a National Veterinary Associates property for $3.5 million. The property is located in Connecticut and is corporate-operated under a new long-term, triple net lease with annual rent bumps. The transaction was priced at a cap rate in range with previous FCPT transactions.

FCPT

FCPT Announces Acquisition Of A National Veterinary Associates Property For $3.5M

Wilmington, Del., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) announced today that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions.
Ashland's Avoca business supplies Sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin.&nbsp; The Avoca business line represents the last entity from Ashland's previous acquisition of Pharmachem.

Asset Sales

Ashland Signs Definitive Agreement To Sell Avoca Business To Mane; Expected To Close In Q1 2025; No Financial Terms Disclosed

KORE Group Holdings, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>)&nbsp;("KORE" or the "Company"), the global pure-play Internet of Things ("IoT") hyperscaler and provider of IoT Connectivity, Solutions, and Analytics, today announced it has received notification (the "Acceptance Letter") from the New York Stock Exchange (the "NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listing standards set forth in Section 802.01B of the NYSE Listed Company Manual relating to minimum market capitalization and stockholders' equity. In the Acceptance Letter, the NYSE granted the Company an 18-month period from September 12, 2024 (the "Plan Period") to regain compliance with the continued listing standards. As part of the Plan, the Company is required to provide the NYSE quarterly updates regarding its progress towards the goals and initiatives in the Plan. In the Plan, Kore included details regarding previously reported operational restructuring activities, as well as an outlook on the Company's business.&nbsp;

KORE

KORE Announces NYSE Granted The Company An 18-Month Period From September 12, 2024 To Regain Compliance With The Continued Listing Standards

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) has outperformed the market over the past 10 years by 1.8% on an annualized basis producing an average annual return of 12.9%. Currently, Guidewire Software has a market capitalization of $14.36 billion. 
Buying $100 In GWRE: If an investor had bought $100 of GWRE stock 10 years ago, it would be worth $333.15 today based on a price of $173.74 for GWRE at the time of writing.
<h3>Guidewire Software's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734991208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GWRE

Here's How Much $100 Invested In Guidewire Software 10 Years Ago Would Be Worth Today

Company Priorities for 2025
Looking at both the improvements in the base business and the advances we made with vagus nerve stimulation (VNS), we have a lot to be proud of in 2024.
I am even more pleased we accomplished all of this while slashing our net operating loss by more than 30%.
As we look to 2025,
<ul>
<li>We are exploring new opportunities to increase cash flow generated by the ClearUP business.</li>
<li>We look forward to completing the current work with Feinstein Institute of Bioelectronic Medicine.</li>
<li>We are charting disease-specific clinical trials, moving the company closer to securing regulatory approvals for what we expect will be life-changing treatments for patients in need.</li>
<li>We look forward to talking in more detail about the specific target indications as we advance into the next stage of clinical trial work in 2025.</li>
</ul>
We anticipate that the advancement of our clinical programs for ncVNS will be key to increasing long-term shareholder value. In addition, the board and I continue to evaluate a range of options to maximize shareholder returns, including taking the necessary steps to ensure we regain Nasdaq listing compliance.
I would like to recognize the exceptional efforts of the lean and dedicated Tivic Health team. I thank them for their relentless drive and hard work. Together, with our investors, collaborators, and supporters, we are striving to build a company that can transform the future of medicine and make a lasting, positive impact on the lives of people around the world.
We are excited about the opportunities that lie ahead, and we look forward to continuing this journey with all of you in 2025.
Sincerely,
Jennifer Ernst Chief Executive Officer

Guidance

TIVC

Tivic Health CEO Outlines 2025 Priorities, Sees 30% Reduction in Net Operating Loss, ClearUP Cash Flow Initiatives, ncVNS Clinical Programs To Boost Shareholder Value, Collaboration With Feinstein Institute, And Plans For Nasdaq Compliance

On Sunday, Jeff Bezos, founder of Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), denied rumors that he has planned a $600 million wedding to marry his fiancée, Lauren Sanchez. Bezos and several other celebrities reacted to the since-debunked<a href="https://www.benzinga.com/general/entertainment/24/12/42639012/inside-jeff-bezos-600m-wedding-to-lauren-sanchez-luxe-decor-stars-and-romance"> report on social media.</a>&nbsp;&nbsp;
What To Know: The Bezos wedding rumor originated on Saturday with <a href="https://www.dailymail.co.uk/news/article-14217859/Jeff-Bezos-Lauren-Sanchez-wedding-plan-Aspen-date-is.html">a report</a> from the Daily Mail alleging the couple would marry in a $600 million dollar ceremony at Kevin Costner&#8217;s Dunbar Ranch in Aspen.&nbsp;&nbsp;
Other media outlets picked up the story and billionaire investor Bill Ackman questioned the validity of the report in a response to a story from the NY Post.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is not credible. Unless you are buying each of your guests a house, you can't spend this much money. <a href="https://t.co/1TVGOBLe9D">https://t.co/1TVGOBLe9D</a>
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1870814198898258422?ref_src=twsrc%5Etfw">December 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next: <a href="https://www.benzinga.com/24/12/42653466/honda-nissan-plan-to-merge-in-the-face-of-chinese-ev-competition">Honda, Nissan Confirm Merger Plans To Offset Chinese EV Competition: How Mitsubishi Factors In</a>
Bezos then responded to Ackman's post with a full denial of the rumored wedding.&nbsp;
&#8216;This whole thing is completely false &#8211; none of this is happening,&#8217; he posted on X. &#8216;The old adage &#8220;don&#8217;t believe everything you read&#8221; is even more true today than it ever has been.&#8217;
&#8216;Now lies can get ALL the way around the world before the truth can get its pants on. So be careful out there folks and don&#8217;t be gullible,&#8217; Bezos said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Furthermore, this whole thing is completely false — none of this is happening. The old adage "don't believe everything you read" is even more true today than it ever has been. Now lies can get ALL the way around the world before the truth can get its pants on. So be careful out… <a href="https://t.co/wz2SWp6wBZ">https://t.co/wz2SWp6wBZ</a>
&mdash; Jeff Bezos (@JeffBezos) <a href="https://twitter.com/JeffBezos/status/1870833626079752672?ref_src=twsrc%5Etfw">December 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Elon Musk, currently the richest man in the world, also responded to the social media thread with well-wishes for his rival. Musk said that &#8220;even if one is not present,&#8221; he hopes Bezos holds &#8220;an epic wedding&#8221; in the future. 
Bezos is currently the second-richest man in the world, <a href="https://www.bloomberg.com/billionaires/">according </a>to Bloomberg, and the men have battled for first place in the past. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">That said, I hope you do hold an epic wedding. It's nice to know that epic events are happening somewhere in the world, even if one is not present. A world where there are amazing events somewhere is better than a world where they are happening nowhere.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1870884997848281263?ref_src=twsrc%5Etfw">December 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Michael Saylor, chairman of MicroStrategy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) and outspoken Bitcoin advocate, also responded to Bezos' denial of the $600 million wedding rumors.&nbsp;
"$600M would buy a lot of Bitcoin," Saylor posted.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">$600M would buy a lot of Bitcoin.
&mdash; Michael Saylor&#x26a1;&#xFE0F; (@saylor) <a href="https://twitter.com/saylor/status/1870855350372749702?ref_src=twsrc%5Etfw">December 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What Else: Though Bezos denied rumors of an upcoming Aspen nuptial, he did not give any details about when or where a wedding may take place for the couple. Bezos, 60, and Sanchez, 55, have been engaged since May 2023 and have remained relatively tight-lipped regarding their wedding plans.&nbsp;
&#8220;We're still thinking about the wedding,&#8221; Sanchez told<a href="https://www.vogue.com/article/lauren-sanchez-december-2023-interview-profile"> Vogue</a> in November 2023.
&#8220;What it's going to be. Is it going to be big? Is it going to be overseas? We don't know yet. We've only been engaged five months!&#8221; she said. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/12/42598651/mystery-drone-sightings-all-over-the-country-trump-says-what-to-know-about-investigations-lawmakers-reactions">&#8216;Mystery Drone&#8217; Sightings Spark Investigations, Politicians Respond: &#8216;Shoot Them Down,&#8217; Trump Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

MSTR

Jeff Bezos Says $600 Million Wedding Rumor Is 'Completely False': Elon Musk, Michael Saylor, Bill Ackman Respond

Quoin Pharmaceuticals GAAP EPS of -$0.47 misses by $0.01

Naz Rahman, an analyst from Maxim Group, has initiated a new Buy rating on Quoin Pharmaceuticals (QNRX). Naz Rahman has given his Buy rating due to...

Promising Developments and Financial Stability Propel Quoin Pharmaceuticals' Buy Rating

Quoin Pharmaceuticals Ltd (QNRX) has disclosed a new risk, in the Share Price & Shareholder Rights category. Quoin Pharmaceuticals Ltd faces a sign...

Quoin Pharmaceuticals at Risk of Nasdaq Delisting Amidst Financial Challenges

Quoin Pharmaceuticals ( ($QNRX) ) has shared an update. Quoin Pharmaceuticals Ltd. held its 2024 Annual General Meeting where shareholders approved...

Quoin Pharmaceuticals Annual Meeting Approves Key Amendments

Maxim Group is acting as the exclusive placement agent for this offering. Published first on TheFly – the ultimate source for real-time, market-mov...

Quoin Pharmaceuticals files to sell 19.23M ordinary shares

Quoin Pharmaceuticals announces 19.23M equity offering

Quoin Pharmaceuticals (QNRX) announces interim clinical data from two of its ongoing Netherton Syndrome clinical studies. Data from the first subje...

Quoin Pharmaceuticals announces interim data from Netherton Syndrome studies

Quoin Pharmaceuticals (QNRX) announces FDA clearance to initiate a new additional Netherton Syndrome clinical study for QRX003. QRX003 is a topical...

Quoin Pharmaceuticals announces FDA clearance to initiate QRX003 study

Quoin Pharmaceuticals (QNRX) announced the pricing of its "reasonable best efforts" public offering of 15,111,110 ordinary shares represented by 15...

Quoin Pharmaceuticals prices 15.1M ADSs at 45c in public offering

Quoin Pharmaceuticals announces pricing of $6.8 million public offering

Health Care

Press Releases

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Management

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Aditxt

Aptevo Therapeutics

Anitra

Bone Biologics

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Entero Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

NuCana

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Quoin Pharmaceuticals

Quoin Pharmaceuticals (QNRX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga